Although direct evidence supporting its ability to maintain normoglycemia after drug withdrawal according to current consensus definitions of remission is lacking, chiglitazar sodium’s pronounced effects on improving insulin sensitivity and preserving β-cell function position it as a leading candidate for future research targeting diabetes remission. This evidence concerns the gene INS and diabetes mellitus.